CEO: Helen I. Torley

Sector: Health Technology
Industry:Biotechnology

Exchange: NASDAQ

Country: US

Description: Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.


Key numbers

Market Capitalization:3620827900
Shares Outstanding: 135815000
Float: 126991914
Next Earning Date:2020-08-10
TTm EPS: -0.5601
TTm Dividend Rate:
200 days moving average:20.62
50 days moving average: 25.69
One day percent Change: 4.27



2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,